Retatrutide vs Semaglutide vs Tirzepatide
GLP-1 research peptides · UAE
The three most-studied metabolic research peptides differ mainly in how many incretin receptors they engage. Here's how they compare, and where to source each in the UAE.
| Compound | Receptors | Sizes | From | |
|---|---|---|---|---|
| Semaglutide | GLP-1 research peptide | 10 mg | AED 259 | View → |
| Tirzepatide | Dual GIP/GLP-1 research peptide | 10 mg · 30 mg | AED 359 | View → |
| Retatrutide | Triple-agonist research peptide | 10 mg · 30 mg | AED 379 | View → |
How to think about them
- Semaglutide — single GLP-1 receptor agonist; the long-standing metabolic reference compound.
- Tirzepatide — dual GLP-1 + GIP; studied when two incretin pathways matter.
- Retatrutide — triple GLP-1 + GIP + glucagon; the newest, broadest-coverage reference.
Source research-grade GLP-1 peptides in the UAE
99%+ verified purity, COA on every batch, fast discreet delivery across the UAE & GCC.
Browse all peptides →Frequently asked questions
Which is the newest?
Retatrutide is the newest of the three — a triple agonist (GLP-1, GIP and glucagon), studied as the broadest-coverage metabolic reference compound.
What is the difference between them?
Semaglutide targets the GLP-1 receptor; Tirzepatide is a dual GLP-1/GIP agonist; Retatrutide adds the glucagon receptor for triple action. Research use only.
Do you deliver in the UAE?
Yes — fast, discreet delivery across the UAE and GCC, with a COA on every batch.
For research use only. Not for human or animal consumption; not medical or dosing advice. Must be 21+ to purchase.